All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene and Roche, and supported through educational grants from Bristol Myers Squibb, Ipsen Biopharmaceuticals, Lilly, Pfizer, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC View funders.
Bookmark this article
On 1 November 2018, the European Commission (EC) granted approval to venetoclax in combination with rituximab for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL) who have received at least one prior therapy. This comes after the regimen of venetoclax in combination with rituximab for the treatment of people with previously treated CLL or small lymphocytic lymphoma (SLL), with or without 17p deletion was granted approval by the US Food and Drug Administration (FDA) in June 2018.1
The EC approval was based on results from the multicenter, open-label, randomized phase III MURANO trial (NCT02005471), which evaluated the efficacy and safety of venetoclax in combination with rituximab (n = 194) compared with bendamustine in combination with rituximab (n = 195) in 389 patients (median age = 65 years; range, 22–85) with R/R CLL who had received at least one prior therapy.2
The phase III MURANO study met its primary endpoint, investigator (INV)-assessed progression-free survival (PFS), in which patients who were treated with venetoclax plus rituximab had a significant reduction in the risk of disease progression or death by 83% (HR = 0.17, P < 0.0001) compared to patients treated with bendamustine in combination with rituximab. In addition, patients in the venetoclax plus rituximab arm had a better overall survival (OS) compared to bendamustine in combination with rituximab, a standard of care chemoimmunotherapy regimen (2-year OS, 91.9% vs 86.6% respectively, HR = 0.48) .1,2
Undetectable minimal residual disease (MRD) was the secondary endpoint of the phase III MURANO study. Professor Peter Hillmen, St James's University Hospital, Leeds, UK, discussed the results from the MRD kinetics of the MURANO study in an interview with Lymphoma Hub. He noted that "a key secondary endpoint was MRD eradication from peripheral blood." He said that after 9 months of therapy, "there was a much higher rate of MRD reduction with venetoclax plus rituximab, 62%, compared with bendamustine plus rituximab, 13%." He concluded that "MRD is an important endpoint in CLL as it shows that venetoclax plus rituximab is a more effective therapy."
According to the drug manufacturers, the approval by the EC makes venetoclax plus rituximab the “first chemotherapy-free combination with a 24-month fixed duration for the treatment of patients with CLL who have received at least one prior therapy.”1
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Your opinion matters
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox